查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008498

神經退化性疾病治療市場：按類型、藥物類別、給藥途徑、作用機制、治療方法、適應症、患者群體、銷售管道和最終用戶分類－2026-2032年全球市場預測

Neurodegenerative Drugs Market by Type, Drug Class, Mode Of Administration, Mechanism Of Action, Therapeutic Approach, Indication, Patient Demographics, Sales Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，神經退化性疾病治療市場價值將達到 477.9 億美元，到 2026 年將成長至 513.9 億美元，到 2032 年將達到 815.1 億美元，複合年成長率為 7.92%。

主要市場統計數據
基準年 2025 477.9億美元
預計年份：2026年 513.9億美元
預測年份 2032 815.1億美元
複合年成長率 (%) 7.92%

本文將揭示在史無前例的科學和政策變革中，神經退化性疾病治療的研究和市場發展的基礎。

在全球人口老化和疾病機制複雜多樣的背景下，神經退化性疾病已成為現代醫療保健面臨的最複雜挑戰之一。阿茲海默症、帕金森氏症、肌萎縮性側索硬化症（ALS）和多發性硬化症等疾病日益增多，亟需開發新的治療策略，同時緩解症狀並延緩疾病進展。為了因應這些需求，分子生物學、基因編輯和生物標記發現領域的突破性進展正在重新定義藥物研發的典範。

本文探討了神經退化性疾病治療領域發生的變革性變化，這些變化是由突破性發現和對監管框架的根本性重新評估所驅動的。

神經退化性疾病治療領域正經歷著一場翻天覆地的變革，主要得益於科學的進步和監管理念的轉變。精準醫療的發展使得人們能夠發現新的分子標靶，並開發出能夠延緩或阻止疾病進展的治療方法。基因療法、單株抗體和小分子調變器的創新正在開闢前所未有的干涉途徑。同時，主要市場的監管機構也意識到飽受神經系統疾病折磨的患者的迫切需求，並正在推行擴大適應症許可和有條件核准。

檢驗2025 年美國關稅對神經退化性疾病治療的供應鏈、定價結構和全球競爭力的累積影響。

美國將於2025年實施關稅，這將為神經退化性疾病治療藥物的供應鏈帶來新的複雜性，原料藥）和成品均產生影響。依賴跨國採購的製造商正面臨原物料成本上漲的困境，由此產生的價格壓力波及整個經銷網路。為因應這項挑戰，各公司正努力重組供應鏈，並透過探索替代採購途徑和加強國內生產能力來緩解關稅帶來的成本上漲。

關鍵的市場細分洞察，可指導藥物類型、分類、給藥途徑和患者群體的策略定位。

精準理解市場區隔對於最佳化神經退化性疾病治療領域的研發投資和商業化策略至關重要。分析藥物類型可以發現不同的價值提案，尤其是在品牌藥和學名藥之間。創新品牌藥組合維持高溢價，而學名藥提供了經濟實惠的治療途徑。就藥物類別而言，膽鹼酯酶抑制劑（如多奈哌齊、吡啶斯的明和Rivastigmine）在維持認知功能方面發揮關鍵作用，而脫羧酶抑制劑（如芐絲肼、碳度巴和甲基多巴）則與多巴胺促效劑（如阿撲嗎啡、卡麥角林、Pramipexole和rotigotine）形成互補。免疫調節藥物透過標靶緩解疾病通路，為治療增添了新的維度。

闡明影響主要地區神經退化性疾病治療引進模式和投資重點的關鍵區域動態因素。

區域趨勢對神經退化性疾病治療藥物的引進和投資有顯著影響。在美洲，完善的研究基礎設施和大量的公共及私人資金正在加速尖端療法的開發，而成熟的醫保報銷體系則為商業性擴張提供了支持。該地區的市場參與企業正在利用先進的臨床試驗網路和上市後調查計畫來檢驗真實世界的臨床結果，並提升市場進入。

引領神經退化性疾病治療市場創新、夥伴關係和競爭策略的主要企業。

在神經退化性疾病治療領域，一些機構因其在研發和商業化方面的開創性方法而脫穎而出。這些行業領導者充分利用跨學科合作，並將學術知識與自身研發能力結合，從而加速候選化合物的篩選和臨床前檢驗。透過與生物技術公司和技術供應商建立策略合作夥伴關係，他們能夠利用先進的分析技術和人工智慧來最佳化臨床試驗設計和患者招募策略。

為產業領導者制定切實可行的策略建議，以因應不斷變化的市場環境和監管環境。

要在瞬息萬變的神經退化性疾病治療領域取得成功，產業領導者需要採取多管齊下的策略方針。首先，優先投資於前沿舉措項目，例如基因療法、生物標記主導平台以及與數位醫療的整合，能夠使企業始終處於創新前沿。其次，透過建立區域性製造地和簽訂替代採購合約來實現供應鏈多元化，可以降低關稅波動和地緣政治變化帶來的財務和營運風險。

詳細介紹了整合多維資料來源、專家分析和嚴格檢驗過程的穩健調查方法。

本研究採用綜合調查方法，旨在提供切實可行的見解和可靠的分析。研究基於廣泛的二手資料研究，包括同行評審期刊、監管文件和臨床試驗資料庫，從而了解神經退化性疾病藥物研發的現狀。在此基礎上，研究也與包括神經科醫生、藥理學家和患者權益組織代表在內的關鍵意見領袖（KOL）開展了一手調查，以深入觀點治療需求和藥物應用趨勢。

整合關鍵見解和策略意義，以指導神經退化性疾病領域中相關人員的決策。

這項分析的綜合結果凸顯了神經退化性疾病治療發展正在發生變革性變化。分子標靶和生物標記識別的科學突破，與加速患者獲得治療的監管創新相輔相成。同時，在不斷變化的關稅政策和供應鏈趨勢下，適應性強的商業策略對於維持成本效益和全球競爭力至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：神經退化性疾病治療市場：依類型分類

  • 品牌商品
  • 學名藥

第9章：神經退化性疾病治療市場：依藥物類別分類

  • 膽鹼酯酶抑制劑
    • 多奈哌齊
    • 吡啶斯的明
    • Rivastigmine
  • 脫羧酶抑制劑
    • 芐絲肼
    • 碳度巴
    • 甲基多巴
  • 多巴胺促效劑
    • 阿撲嗎啡
    • 卡麥角林
    • Pramipexole
    • rotigotine
  • 免疫調節藥物

第10章：依給藥途徑分類的神經退化性疾病治療藥物市場

  • 注射藥物
  • 口服
  • 經皮貼劑

第11章：按作用機轉分類的神經退化性疾病治療藥物市場

  • 離子通道調變器
    • 鉀通道調變器
    • 鈉通道調變器
  • 突觸調變器

第12章：依治療方法分類的神經退化性疾病治療市場

  • 神經保護
    • 抗發炎藥
    • 抗氧化劑
  • 預防性治療
  • 症狀治療

第13章：神經退化性疾病治療市場：依適應症分類

  • 阿茲海默症
  • 肌萎縮側索硬化症（ALS）
  • 多發性硬化症
    • 原發性進行性
    • 復發緩解型
  • 帕金森氏症

第14章：依病患細分分類的神經退化性疾病治療市場

  • 成人版
  • 老年人
  • 兒童

第15章：神經退化性疾病治療市場：依銷售管道分類

  • 離線
    • 醫院和藥房
    • 零售藥房
  • 線上

第16章：神經退化性疾病治療市場：依最終用戶分類

  • 診所
  • 合約研究機構
  • 醫院
  • 研究機構

第17章：神經退化性疾病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第18章：神經退化性疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第19章：神經退化性疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第20章：美國神經退化性疾病治療藥物市場

第21章：中國神經退化性疾病治療藥物市場

第22章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • ACADIA Pharmaceuticals Inc.
  • Alpha Cognition Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aquinnah Pharmaceuticals Inc.
  • Asceneuron SA
  • AstraZeneca PLC
  • AZTherapies, Inc.
  • Bausch Health Companies Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Denali Therapeutics Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin International plc
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation by Smiths Group plc
  • Pfizer, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Theravance Biopharma
  • UCB SA
Product Code: MRR-C002B1C996F9

The Neurodegenerative Drugs Market was valued at USD 47.79 billion in 2025 and is projected to grow to USD 51.39 billion in 2026, with a CAGR of 7.92%, reaching USD 81.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 47.79 billion
Estimated Year [2026] USD 51.39 billion
Forecast Year [2032] USD 81.51 billion
CAGR (%) 7.92%

Unveiling the Foundations of Neurodegenerative Drug Research and Market Evolution Amidst Unprecedented Scientific and Policy Disruptions

Neurodegenerative disorders present one of the most complex challenges to modern healthcare, driven by an aging global population and multifactorial disease mechanisms. Conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis have propelled the need for novel therapeutic strategies that address both symptoms and underlying disease progression. Amid this imperative, breakthroughs in molecular biology, gene editing, and biomarker discovery are redefining the paradigms of drug development.

At the same time, regulatory landscapes are evolving to accommodate accelerated approval pathways and expanded access frameworks, creating a more flexible environment for innovators to bring therapies to patients in need. The integration of real-world evidence and digital health platforms has enhanced clinical trial design, enabling more precise patient stratification and adaptive study protocols. Collaborative models between academic institutions, biotechnology startups, and established pharmaceutical companies are further accelerating the translation of preclinical insights into clinical candidates.

Looking ahead, the focus is shifting towards holistic approaches that combine neuroprotection, immunomodulation, and synaptic support. Stakeholders are increasingly evaluating combination therapies and leveraging artificial intelligence to optimize drug discovery pipelines. This introduction sets the stage for an in-depth exploration of the transformative shifts, policy impacts, segmentation nuances, regional dynamics, and strategic imperatives that define the future of neurodegenerative drug development.

Tracing the Transformative Shifts in Neurodegenerative Therapy Landscape Fueled by Breakthrough Discoveries and Regulatory Overhauls

The neurodegenerative drug landscape is undergoing a profound metamorphosis, catalyzed by converging scientific advances and shifts in regulatory philosophy. Precision medicine initiatives have identified novel molecular targets, enabling the development of therapies that may slow or halt disease progression. Innovations in gene therapy, monoclonal antibodies, and small molecule modulators are offering unprecedented avenues for intervention. Concurrently, regulatory bodies across major markets have introduced adaptive licensing schemes and conditional approvals, recognizing the urgent unmet needs of patients affected by debilitating neurological conditions.

In parallel, technological advancements in imaging, fluid biomarkers, and omics analytics are refining diagnostic criteria and enabling earlier intervention. Digital therapeutics and remote monitoring devices are enhancing patient engagement and supporting data-driven decision making. This ecosystem of innovation has fostered strategic alliances, where biopharma companies collaborate with technology firms to co-develop integrated solutions that extend beyond traditional pharmacotherapy.

As a result, clinical trial paradigms are evolving towards decentralized models and master protocols, reducing time to market and improving the efficiency of patient recruitment. These transformative shifts not only accelerate access to cutting-edge treatments but also redefine competitive dynamics, compelling stakeholders to reevaluate their pipelines, partnerships, and go-to-market strategies in light of an increasingly agile and patient-centric environment.

Examining the Cumulative Effects of 2025 US Tariffs on Neurodegenerative Drug Supply Chains, Pricing Structures, and Global Competitiveness

The implementation of United States tariffs in 2025 has introduced a new layer of complexity to the neurodegenerative drug supply chain, impacting both active pharmaceutical ingredients and finished formulations. Manufacturers reliant on cross-border sourcing have encountered elevated input costs, leading to pricing pressures that reverberate throughout distribution networks. In response, companies have initiated supply chain realignment efforts, exploring alternative procurement corridors and reinforcing domestic manufacturing capabilities to mitigate tariff-driven cost escalations.

These developments have altered global competitiveness, particularly for firms exporting to or from regions with disparate tariff frameworks. Negotiations with contract manufacturing organizations and distribution partners now emphasize risk-sharing arrangements and flexible contract terms to absorb additional financial burdens. At the same time, pricing committees and reimbursement agencies are closely monitoring tariff-induced cost fluctuations, requiring more transparent cost-justification frameworks.

Looking forward, industry players are increasingly adopting dynamic pricing strategies and leveraging trade agreements to optimize cross-border operations. Collaboration with regulatory authorities and trade bodies has become essential to navigate evolving tariff schedules and to advocate for policy adjustments that recognize the critical nature of neurodegenerative therapies. This analysis highlights the cumulative impact of tariff policies on market dynamics, underscoring the need for adaptive supply chain resilience and strategic cost management.

Illuminating Critical Market Segmentation Insights That Inform Strategic Positioning Across Drug Types Classes Administration Modes and Patient Profiles

A nuanced understanding of market segmentation is essential for tailoring R&D investments and commercialization strategies within the neurodegenerative drug space. When examined by type, the distinction between branded and generic therapies reveals divergent value propositions, with innovative brand portfolios commanding premium pricing while generics offer cost-effective access. Within drug classes, cholinesterase inhibitors such as donepezil, pyridostigmine and rivastigmine play a key role in cognitive support, whereas decarboxylase inhibitors like benserazide, carbidopa and methyldopa complement dopamine agonists including apomorphine, cabergoline, pramipexole and rotigotine. Immunomodulators add another dimension by targeting disease-modifying pathways.

Mode of administration further segments the market into injectable, oral, and transdermal patch formats, influencing patient adherence and route-specific efficacy. Mechanisms of action are delineated between ion channel modulators-spanning potassium and sodium channel regulators-and synaptic modulators that address neurotransmitter dynamics. Therapeutic approaches divide into neuroprotection, preventive treatment and symptomatic relief, with neuroprotective strategies encompassing anti-inflammatory agents and antioxidants. Indication-based segmentation highlights applications in Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis-with primary progressive and relapsing-remitting subtypes-and Parkinson's disease. Patient demographics reveal distinct usage patterns across adult, geriatric and pediatric cohorts, while sales channels, whether offline through hospital and retail pharmacies or online platforms, shape distribution dynamics. Finally, end users spanning clinics, contract research organizations, hospitals and research institutes drive demand based on clinical and investigational needs.

Together, these segmentation insights empower leaders to align product development, pricing models and market entry strategies with the diverse needs of stakeholders across the value chain.

Uncovering Key Regional Dynamics Shaping Neurodegenerative Drug Adoption Patterns and Investment Priorities Across Major Geographies

Regional dynamics exert a profound influence on the trajectory of neurodegenerative drug adoption and investment. In the Americas, robust research infrastructure and significant public and private funding have accelerated the development of cutting-edge therapeutics, while established reimbursement frameworks support commercial scalability. Market participants in this region are leveraging advanced clinical trial networks and post-market surveillance programs to validate real-world outcomes and reinforce market access.

Across Europe, the Middle East and Africa, heterogeneous regulatory environments present both challenges and opportunities. Countries with streamlined approval pathways and patient access schemes foster innovation, whereas regions with constrained healthcare budgets demand tailored cost-benefit justifications. Geographic nuances in disease prevalence, healthcare spending and care delivery models further guide strategic partnerships and localized R&D initiatives.

The Asia-Pacific region is characterized by rapid urbanization, rising healthcare expenditure and expanding clinical trial capacity. A growing middle-class population and favorable policy incentives are attracting global players to establish manufacturing hubs and research centers. Local regulatory bodies are increasingly harmonizing guidelines with international standards, promoting faster market entry for novel therapies. Understanding these distinct regional landscapes enables stakeholders to optimize portfolio allocation, forge strategic alliances and adapt commercialization strategies to the unique parameters of each geography.

Highlighting Leading Industry Players Driving Innovation Partnerships and Competitive Strategies in the Neurodegenerative Drug Market

Within the neurodegenerative drug arena, certain organizations stand out for their pioneering approaches to research, development and commercialization. These industry leaders leverage cross-disciplinary collaborations, integrating academic insights with in-house R&D capabilities to accelerate candidate selection and preclinical validation. Strategic alliances with biotechnology firms and technology providers have allowed them to harness advanced analytics and artificial intelligence, optimizing trial design and patient recruitment strategies.

Furthermore, these companies are redefining the competitive landscape through targeted acquisitions and licensing agreements, expanding their pipelines to include both disease-modifying and symptomatic treatments. Their focus on specialty formulations and novel delivery systems has improved therapeutic outcomes and patient adherence. In parallel, they maintain robust portfolios of biomarkers and companion diagnostics, enabling more precise patient stratification and personalized care models.

To sustain their market leadership, these players continually strengthen their global footprint. They invest in manufacturing capacity, secure strategic partnerships for distribution, and engage proactively with regulatory agencies to navigate complex approval pathways. By combining financial resilience with scientific excellence, these companies set the benchmark for innovation, operational efficiency and commercial success in the neurodegenerative drug sector.

Formulating Actionable Strategic Recommendations for Industry Leaders to Navigate Evolving Market Landscapes and Regulatory Environments

To thrive in the dynamic field of neurodegenerative therapeutics, industry leaders must adopt a multi-faceted strategic approach. First, prioritizing investment in cutting-edge R&D initiatives, including gene therapies, biomarker-driven platforms and digital health integrations, will position organizations at the forefront of innovation. Second, diversifying supply chains by establishing regional manufacturing hubs and securing alternative sourcing agreements can mitigate the financial and operational risks associated with tariff fluctuations and geopolitical shifts.

In addition, fostering collaborative ecosystems with technology partners, academic centers and patient advocacy groups will accelerate translational research and enhance stakeholder engagement. This collaborative ethos should extend to regulatory strategy, where early dialogue with health authorities can streamline approval pathways and align clinical trial endpoints with payer expectations. Moreover, implementing patient-centric programs that support adherence, education and long-term outcomes will strengthen market access and underpin value-based care models.

Finally, organizations must refine their commercial strategies through dynamic pricing frameworks and adaptive go-to-market plans that reflect regional nuances and evolving reimbursement landscapes. By executing these recommendations, industry leaders can navigate uncertainties, capitalize on emerging opportunities and deliver meaningful therapeutic advances to patients living with neurodegenerative conditions.

Detailing a Robust Research Methodology Integrating Multidimensional Data Sources Expert Analyses and Rigorous Validation Processes

This study employs a comprehensive research methodology designed to deliver actionable insights and reliable analysis. The foundation rests on extensive secondary research, incorporating peer-reviewed journals, regulatory filings and clinical trial databases to map the current state of neurodegenerative drug development. Building on this, primary research engagements with key opinion leaders, including neurologists, pharmacologists and patient advocacy representatives, provide nuanced perspectives on therapeutic needs and adoption trends.

Quantitative analysis leverages real-world evidence and proprietary datasets, employing statistical validation techniques to ensure data integrity and reproducibility. Qualitative insights from expert interviews and roundtable discussions enrich the quantitative findings, identifying emerging themes and potential inflection points. The methodology also includes a thorough review of policy frameworks, trade agreements and tariff schedules to assess regulatory impacts on supply chains and pricing structures.

Data triangulation and scenario analysis further validate the robustness of conclusions, while peer benchmarking and portfolio mapping contextualize competitive positioning. This multi-dimensional approach ensures that the study's conclusions are grounded in empirical evidence, expert judgment and strategic foresight, equipping stakeholders with the insights needed to make informed decisions in the neurodegenerative drug domain.

Synthesizing Core Findings and Strategic Implications to Guide Stakeholder Decisions in the Neurodegenerative Drug Domain

The synthesis of this analysis underscores the transformative trajectories reshaping neurodegenerative drug development. Scientific breakthroughs in molecular targeting and biomarker identification are complemented by regulatory innovations that accelerate patient access. At the same time, evolving tariff policies and supply chain dynamics necessitate adaptive operational strategies to maintain cost efficiency and global competitiveness.

Segmenting the market by drug type, class, administration mode, mechanism of action, therapeutic approach, indication, demographics, sales channel and end user reveals the nuanced pathways to value creation. Regionally tailored strategies highlight the importance of understanding local regulatory frameworks, reimbursement models and healthcare infrastructure. Leading industry players demonstrate the competitive advantages of strategic partnerships, pipeline diversification and technology integration.

Actionable recommendations emphasize the need for investment in advanced R&D, supply chain resilience, collaborative ecosystems, regulatory engagement and patient-centric care models. Rigorous methodological validation ensures that these insights are not only evidence-based but also forward-looking, preparing stakeholders to navigate future uncertainties. This conclusion ties together the study's core findings, offering a clear roadmap for decision-makers seeking to capitalize on the opportunities presented by the evolving landscape of neurodegenerative therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurodegenerative Drugs Market, by Type

  • 8.1. Branded
  • 8.2. Generics

9. Neurodegenerative Drugs Market, by Drug Class

  • 9.1. Cholinesterase Inhibitors
    • 9.1.1. Donepezil
    • 9.1.2. Pyridostigmine
    • 9.1.3. Rivastigmine
  • 9.2. Decarboxylase Inhibitors
    • 9.2.1. Benserazide
    • 9.2.2. Carbidopa
    • 9.2.3. Methyldopa
  • 9.3. Dopamine Agonist
    • 9.3.1. Apomorphine
    • 9.3.2. Cabergoline
    • 9.3.3. Pramipexole
    • 9.3.4. Rotigotine
  • 9.4. Immunomodulators

10. Neurodegenerative Drugs Market, by Mode Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Transdermal Patch

11. Neurodegenerative Drugs Market, by Mechanism Of Action

  • 11.1. Ion Channel Modulators
    • 11.1.1. Potassium Channel Modulators
    • 11.1.2. Sodium Channel Modulators
  • 11.2. Synaptic Modulators

12. Neurodegenerative Drugs Market, by Therapeutic Approach

  • 12.1. Neuroprotection
    • 12.1.1. Anti-Inflammatory Agents
    • 12.1.2. Antioxidants
  • 12.2. Preventive Treatment
  • 12.3. Symptomatic Treatment

13. Neurodegenerative Drugs Market, by Indication

  • 13.1. Alzheimer's Disease
  • 13.2. Amyotrophic Lateral Sclerosis (ALS)
  • 13.3. Multiple Sclerosis
    • 13.3.1. Primary Progressive
    • 13.3.2. Relapsing-Remitting
  • 13.4. Parkinson's Disease

14. Neurodegenerative Drugs Market, by Patient Demographics

  • 14.1. Adult
  • 14.2. Geriatric
  • 14.3. Pediatric

15. Neurodegenerative Drugs Market, by Sales Channel

  • 15.1. Offline
    • 15.1.1. Hospitals Pharmacies
    • 15.1.2. Retail Pharmacies
  • 15.2. Online

16. Neurodegenerative Drugs Market, by End User

  • 16.1. Clinics
  • 16.2. Contract Research Organizations
  • 16.3. Hospitals
  • 16.4. Research Institutes

17. Neurodegenerative Drugs Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Neurodegenerative Drugs Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Neurodegenerative Drugs Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. United States Neurodegenerative Drugs Market

21. China Neurodegenerative Drugs Market

22. Competitive Landscape

  • 22.1. Market Concentration Analysis, 2025
    • 22.1.1. Concentration Ratio (CR)
    • 22.1.2. Herfindahl Hirschman Index (HHI)
  • 22.2. Recent Developments & Impact Analysis, 2025
  • 22.3. Product Portfolio Analysis, 2025
  • 22.4. Benchmarking Analysis, 2025
  • 22.5. Abbott Laboratories
  • 22.6. AbbVie Inc.
  • 22.7. ACADIA Pharmaceuticals Inc.
  • 22.8. Alpha Cognition Inc.
  • 22.9. Amneal Pharmaceuticals, Inc.
  • 22.10. Aquinnah Pharmaceuticals Inc.
  • 22.11. Asceneuron SA
  • 22.12. AstraZeneca PLC
  • 22.13. AZTherapies, Inc.
  • 22.14. Bausch Health Companies Inc.
  • 22.15. Biogen Inc.
  • 22.16. Boehringer Ingelheim International GmbH
  • 22.17. Denali Therapeutics Inc.
  • 22.18. Eli Lilly and Company
  • 22.19. GlaxoSmithKline PLC
  • 22.20. H. Lundbeck A/S
  • 22.21. Johnson & Johnson Services, Inc.
  • 22.22. Kyowa Kirin International plc
  • 22.23. Lupin Limited
  • 22.24. Merck & Co., Inc.
  • 22.25. Novartis AG
  • 22.26. Orion Corporation by Smiths Group plc
  • 22.27. Pfizer, Inc.
  • 22.28. Sanofi SA
  • 22.29. Takeda Pharmaceutical Company Limited
  • 22.30. Theravance Biopharma
  • 22.31. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEURODEGENERATIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 17. CHINA NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. GCC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 309. GCC NEURODEGENE